Industry

FDA grants 510(k) clearance to Fsyx ocular pressure adjusting pump

Healio Optometry1w ago1 min read

Editor’s note: This is a developing news story. Please check back soon for updates.The FDA granted 510(k) clearance to the Fsyx ocular pressure adjusting pump, a device designed for nocturnal IOP reduction.According to a press release from Balance Ophthalmics, the updated system, which includes a pressure-modulating pump and goggles worn during sleep, adds wireless communication designed to allow ophthalmologists access to patient usage data.“Across 12 clinical studies involving more than 600 eyes, Fsyx demonstrated a 39% mean IOP reduction in nighttime eye pressure with no device-related

Read full article on Healio Optometry

AI Summary

Quick Take

The FDA has granted 510(k) clearance to Balance Ophthalmics’ Fsyx ocular pressure adjusting pump, a wearable device designed to lower intraocular pressure (IOP) specifically during sleep. Clinical data across 12 studies showed a 39% mean reduction in nocturnal IOP, and the updated system now features wireless communication to provide clinicians with objective patient usage data.

Why It Matters

Managing glaucoma often focuses on daytime IOP measurements, yet many patients experience significant pressure spikes while supine during sleep, which can contribute to disease progression despite seemingly controlled office readings. This clearance introduces a non-invasive, mechanical approach to nocturnal IOP management, filling a clinical gap that topical medications often struggle to address effectively. The addition of wireless monitoring also addresses the perennial challenge of patient compliance, allowing for more data-driven management of high-risk cases.

Key Findings

Clinical trials involving more than 600 eyes demonstrated a 39% mean reduction in nighttime intraocular pressure.
The Fsyx system utilizes a pressure-modulating pump and specialized goggles worn by the patient during sleep to regulate IOP.
The device's efficacy and safety profile are supported by a meta-analysis of 12 separate clinical studies.

Key Details

The Fsyx system is the first of its kind to receive 510(k) clearance for nocturnal IOP reduction.
The updated system includes a pressure-modulating pump, goggles, and a new wireless communication interface.
The wireless functionality is specifically designed to allow ophthalmologists to access and review patient usage data remotely.
Balance Ophthalmics developed the technology to address the 'nocturnal gap' in traditional glaucoma management.

Practice Implications

Clinicians may consider this device for glaucoma patients who show signs of progression despite well-controlled daytime IOP or those known to have significant nocturnal spikes. The wireless data feature allows for objective monitoring of adherence, helping to identify whether treatment failure is due to physiological factors or poor patient compliance with the wearable system.

Who's Affected

OphthalmologistsGlaucoma SpecialistsOptometristsPractice Owners

What's Next

Following this clearance, the focus will likely shift to the commercial availability of the updated system and the integration of its data-sharing platform into clinical practice. Providers should look for further information regarding patient selection criteria and insurance coverage for this mechanical therapy.

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.